BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 23731848)

  • 1. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B.
    Cheng PN; Tsai HW; Chiu YC; Ho CH; Wu IC; Chang TT
    J Clin Virol; 2013 Aug; 57(4):323-30. PubMed ID: 23731848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection.
    Zeng DW; Liu YR; Dong J; Zhu YY; Li YB; Chen J; Zheng Q; Jiang JJ
    Mol Med Rep; 2015 May; 11(5):3465-72. PubMed ID: 25592612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of hepatocyte expression of hepatitis B viral antigens with histological activity and viral titer in chronic hepatitis B virus infection: an immunohistochemical study.
    Ramakrishna B; Mukhopadhya A; Kurian G
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1734-8. PubMed ID: 18713304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection.
    Guner R; Karahocagil M; Buyukberber M; Kandemir O; Ural O; Usluer G; Inan D; Koksal I; Baykam N; Hizel K; Yamazhan T; Esen S; Tasyaran MA
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1185-91. PubMed ID: 21934508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
    Demirören K; Kocamaz H; Doğan Y
    Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease.
    Song BC; Cui XJ; Kim HU; Cho YK
    Intervirology; 2006; 49(5):266-73. PubMed ID: 16714855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients.
    Yim SY; Kim TH; Jun SS; Kim ES; Keum B; Seo YS; Yim HJ; Jeen YT; Chun HJ; Lee HS; Um SH; Kim CD; Won NH; Ryu HS
    Gut Liver; 2017 May; 11(3):417-425. PubMed ID: 28208002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B.
    Lapalus M; Laouenan C; Cardoso AC; Estrabaud E; Carvalho-Filho RJ; Zhang Q; Lada O; Appourchaux K; Mouri F; Boyer N; Bedossa P; Asselah T; Martinot-Peignoux M; Marcellin P
    Liver Int; 2015 Sep; 35(9):2082-9. PubMed ID: 25612083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
    Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
    J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume.
    Ke WM; Xie SB; Li XJ; Zhang SQ; Lai J; Ye YN; Gao ZL; Chen PJ
    J Viral Hepat; 2011 Sep; 18(9):637-45. PubMed ID: 21794025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B.
    Chang XJ; Sun C; Chen Y; Li XD; Yu ZJ; Dong Z; Bai WL; Wang XD; Li ZQ; Chen D; Du WJ; Liao H; Jiang QY; Sun LJ; Li YY; Zhang CH; Xu DP; Chen YP; Li Q; Yang YP
    World J Gastroenterol; 2019 Aug; 25(32):4764-4778. PubMed ID: 31528100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV DNA level and antigen concentration in evaluating liver damage of patients with chronic hepatitis B.
    Xie Y; Zhao H; Dai WS; Xu DZ
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):418-22. PubMed ID: 14599951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.
    Martinot-Peignoux M; Carvalho-Filho R; Lapalus M; Netto-Cardoso AC; Lada O; Batrla R; Krause F; Asselah T; Marcellin P
    J Hepatol; 2013 Jun; 58(6):1089-95. PubMed ID: 23369792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.